Radiopharmaceutical supply disruptions and the use of Tc-hydroxymethylene diphosphonate as an alternative to Tc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement.

Miller EJ, Campisi R, Shah NR, McMahon S, Cuddy S, Gallegos-Kattan C, Maurer MS, Damy T, Slart RHJA, Bhatia K, Einstein AJ J Nucl Cardiol. 2022;29(5):2748-2760.

MeSH terms: Amyloidosis; Cardiomyopathies; Diphosphates; Diphosphonates; Humans; Prealbumin; Radiopharmaceuticals; Technetium Tc 99m Pyrophosphate

DOI: 10.1007/s12350-022-03059-5

PubMed Google Scholar

cepia

Clinical Epidemiology and Ageing

Radiopharmaceutical supply disruptions and the use of Tc-hydroxymethylene diphosphonate as an alternative to Tc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement.